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Lactobacilli are generally regarded as safe; however, certain strains have been associated with cases of infection. Our workgroup
has already assessed many functional properties of Lactobacillus kefiri, but parameters regarding safety must be studied before
calling them probiotics. In this work, safety aspects and antimicrobial activity of L. kefiri strains were studied. None of the L. kefiri
strains tested caused 𝛼- or 𝛽-hemolysis. All the strains were susceptible to tetracycline, clindamycin, streptomycin, ampicillin,
erythromycin, kanamycin, and gentamicin; meanwhile, two strains were resistant to chloramphenicol. On the other hand, all L.
kefiri strains were able to inhibit both Gram(+) and Gram(−) pathogens. Regarding the in vitro results, L. kefiri CIDCA 8348
was selected to perform in vivo studies. Mice treated daily with an oral dose of 108 CFU during 21 days showed no signs of pain,
lethargy, dehydration, or diarrhea, and the histological studies were consistent with those findings. Moreover, no differences in
proinflammatory cytokines secretion were observed between treated and control mice. No translocation of microorganisms to
blood, spleen, or liver was observed. Regarding these findings, L. kefiri CIDCA 8348 is a microorganism isolated from a dairy
product with a great potential as probiotic for human or animal use.
1. Introduction
Kefir grains are composed of a complex community of yeasts,
lactic acid, and acetic acid bacteria confined in a matrix of
polysaccharides and proteins [1]. The product obtained by
fermentation of milk using these grains is called “kefir” and
several health-promoting properties have been associated to
its consumption [2–5].
As it is known, probiotics are “live microorganisms
which, administered in adequate amounts, exert a beneficial
effect to the health of the host” [6]. Specific strains of lactic
acid bacteria, in particular some of the genera Lactobacillus,
are extensively used as probiotics [7, 8] since their ability to
modulate the immune system has been demonstrated [9, 10]
as well as their capacity to inhibit the growth or invasion of
pathogenic bacteria and parasites [11–13].
The study of the beneficial properties attributed to iso-
lated microorganisms constitutes a field of great interest
for the development of functional foods. Lactobacilli are
generally regarded as safe (GRAS) and most of them (as Lac-
tobacillus kefiri) are included in the QPS list of the European
Union [14] due to their long history of use in fermented
dairy products and their presence in human intestinal tract.
However, certain Lactobacillus strains have been associated
with cases of sepsis, endocarditis, or bacteremia, mostly in
association with a severe underlying disease [15–18]. On
the other hand, the absence of the acquired antimicrobial
resistance is a very important criterion for evaluating the
safety of lactic acid bacteria (LAB) used as food started or
probiotics [19]. The breakpoints for the antibiotic list were
defined by the European Food Safety Authority (EFSA) in
order to assess the bacterial resistance to antibiotics of human
or veterinary importance [20, 21].
Our workgroup has isolated and characterized numerous
species of LAB and yeasts from kefir, including several strains
of Lactobacillus kefiri [22–24], one of the most predominant
Hindawi Publishing Corporation
BioMed Research International
Volume 2014, Article ID 208974, 7 pages
http://dx.doi.org/10.1155/2014/208974
2 BioMed Research International
Table 1: Minimum inhibitory concentrations (MIC) for antibiotic resistance.
Antibiotics MIC (mg L
−1)
Breakpointsa CIDCA 8321 CIDCA 8345 CIDCA 8348 CIDCA 83115 CIDCA 83111 CIDCA 83113
Ampicillin 2 <0.032 <0.032 <0.032 <0.032 <0.032 <0.032
Clindamycin 1 <0.032 <0.032 <0.032 <0.032 <0.032 <0.032
Chloramphenicol 4 8 16 2 2 1 2
Erythromycin 1 <0.125 <0.125 <0.125 <0.125 <0.125 <0.125
Gentamicin 16 <0.5 <0.5 <0.5 <0.5 <0.5 <0.5
Kanamycin 32 <2 <2 <2 <2 <2 <2
Streptomycin 64 <0.5 <0.5 <0.5 <0.5 <0.5 <0.5
Tetracycline 8 <0.125 <0.125 4 2 4 <0.125
aThese are the recommended breakpoints for heterofermentative lactobacilli EFSA Panel on Additives and Products or Substances used in Animal Feed (2012)
[20].
species present in kefir-fermented milk (ranged from 2 × 108
to 1 × 109 L. kefiri cells mL−1) [25].
We have already demonstrated the potential of L. kefiri
as a probiotic microorganism in vitro after verifying that
secretion products and surface proteins from these hetero-
fermentative lactobacilli exert a protective action against
the invasion of Salmonella enterica serovar Enteritidis [26]
and that they are able to antagonize the cytotoxic effects of
clostridial toxins on Vero cells [27]. On the other hand, it has
been demonstrated that L. kefiri strains are able to preserve a
high percentage of viability after both spray-drying [28, 29]
and freeze-drying procedures [30]. However, no parameter
regarding L. kefiri’s safety was ever evaluated. Since it is
known that both the beneficial properties such as harmful
characteristic are dependent on the strain, the individual
study of the safety of potential probiotic microorganisms
should be considered.
Taking into account the potential of L. kefiri as a novel
probiotic, we reported in thiswork some safety characteristics
of L. kefiri strains, as well as the capacity of strains to produce
antimicrobial compounds against some intestinal pathogens.
2. Materials and Methods
2.1. Bacterial Strains and Culture Conditions. Pure cultures
used in this study comprised Lactobacillus kefiri strains
CIDCA 8321, 8345, 8348, 83111, 83113, and 83115 [23, 31].
These bacteria were cultured in MRS (Difco, Detroit, USA)
for 48 h at 37∘C. The following pathogenic bacteria were
also used, Enterococcus faecalis ATCC 29212, Staphylococcus
aureusATCC 6538, Shigella flexneriATCC 9199, Pseudomona
aeruginosaATCC 15442, a clinical isolate of Salmonella enter-
ica serovar Enteritidis CIDCA 101 (Hospital de Pediatr´ıa Pro-
fessor Juan P. Garrahan, Buenos Aires, Argentina), enterohe-
morrhagic Escherichia coli EDL 933, Listeria monocytogenes
ATCC 7644, and Bacillus cereus ATCC 10876. All mentioned
strains, except B. cereus, were grown using brain heart
infusion (BHI) broth (Biokar Diagnostics, Beauvais, France)
in agitation at 37∘C for 16 h. B. cereus was grown in BHI
growth supplemented with dextrose (Anedra, Argentina)
1 g L−1 (BHIg) in agitation at 37∘C for 16 h.
2.2. Hemolysis. Hemolysis was tested by growth of the
strains on LAPTg agar (peptone 15 g L−1; tryptone 10 g L−1;
dextrose 10 g L−1; yeast extract 10 g L−1; Tween 80 1 g L−1;
and bacteriological agar 15 g L−1) supplemented with 5%
human blood (group O) and incubated for 48 h at 37∘C
under aerobic conditions. The appearance of clear zones
around the bacterial colonies indicated the presence of 𝛽-
hemolysiswhereas green zones around the colonies suggested
𝛼-hemolysis. Enterococcus faecalis ATCC 29212 was included
as a positive hemolytic control.
2.3. Minimum Inhibitory Concentration (MIC) for Antibi-
otic Resistance. The minimum inhibitory concentrations
(MICs) of the antimicrobial agents tested (Table 1) were
determined by broth microdilution according to the ISO
10932/IDF 233 standard from 2010 [32]. All antibiotics
(Sigma-Aldrich, USA) were dissolved for preparing stock
solutions of 1280𝜇gmL−1. Stock solutions were diluted in
LSM broth (90% IST plus 10%MRS) to obtain solutions with
preliminary concentrations in the range of 0.25–128 𝜇gmL−1.
Bacterial inocula were prepared by suspending colonies
from 48 h incubated in MRS medium to 5mL 0.85% NaCl
solution. Subsequently, inocula were adjusted to OD
625 nm
0.18–0.24 and diluted 1 : 500 in LSM broth for inoculation
of microdilution plates by adding 50𝜇L of diluted inoculum
to each well containing 50 𝜇L of an antibiotic solution. In
these conditions, the bacterial inoculum was around 2-3 ×
105 CFUmL−1 in the wells. After incubating plates under
anaerobic conditions at 37∘C for 48 hours, theMICs valuewas
read as the lowest concentration of an antimicrobial agent in
which visible growth was inhibited.
MICs results were compared with the recommended
breakpoints for heterofermentative lactobacilli by the EFSA
Panel on Additives and Products or Substances used in
Animal Feed [20].
2.4. PCR Detection of Chloramphenicol Resistance Gene. Cat,
chloramphenicol acetyltransferase gene, was assessed using
the primers and PCR conditions described by Hummel et
al. [33]. A plasmid from L. reuteri G4 was used as a positive
control.
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2.5. Growth Inhibition of Bacterial Pathogens. The agar spot
test described by Schillinger and Lu¨cke [34] was used. Briefly,
5 𝜇L of a suspension OD
625 nm 1 of L. kefiri strains was spotted
into MRS agar and incubated for 24 h at 37∘C. The following
day, pathogens were seeded into soft BHI agar and plated over
the spotted lactobacilli. After 18 h of incubation at 37∘C, the
inhibition halos were measured. The width of the clear zone
(𝑅) was calculated as follows: 𝑅 = (dInhib − dSpot)/2, where
dInhib is the diameter of the zone without pathogen growth
and dSpot is the diameter of the spot. Inhibition scores are
as follows: negative (−), 𝑅 < 2mm; low inhibition capacity
(+), 2mm < 𝑅 < 5mm; and high inhibition capacity (++),
𝑅 > 6mm. At least three independent experiments were
performed.
2.6. In Vivo Studies
2.6.1. Ethics Statement. All animal procedures were per-
formed in strict accordance with the guidelines issued by the
European Economic Community “86/609.”
2.6.2. Experimental In Vivo Protocol. Male 6-week-old Swiss
albino mice (Janvier, Le Genest Isle, France) were quaran-
tined 2 weeks after arrival and then randomized by body
weight into experimental and control groups of 5–7 animals
each. Mice were housed under standard laboratory condi-
tions with free access to food and water. The temperature
was kept at 22∘C and a 12-hour light/dark schedule was
maintained. Mice received by gavage 108 CFU of L. kefiri
CIDCA 8348 (Lk group) or PBS (control group) daily for 21
days.
2.6.3. Safety Evaluation. Mice were weighted every two days;
behavior and signs of pain were analyzed daily [35]. At
the end of the experimental protocol, ileum and colon
were removed and histological studies were performed using
hematoxylin-eosin staining [36].
2.6.4. Translocation Assay. Liver and spleen were removed
and blood sampleswere collected aseptically. Liver and spleen
were homogenized in 0.1% sterile PBS (0.1 g of organ per mL)
and serially diluted. One hundred microliters of each organ
homogenate or blood was plated on VRBG Agar (Biokar
Diagnostics, Beauvais, France) for enterobacteria and MRS
agar for LAB. Plates were incubated under aerobic conditions
for 24 h at 37∘C for VRBG and for 48 h at 37∘C forMRS before
examination.
2.6.5. Microorganism Counts in the Ileum. Ileum content was
washed with 1mL sterile PBS and then serial dilutions were
plated as indicated above.
2.6.6. Cytokine Release by Intestine and Colon Explants.
Explants were cultured in RPMImedium supplemented with
10% foetal bovine serum (Gibco-Invitrogen, Carlsbad, CA,
USA), 10mg/L streptomycin and 10 IU/mL penicillin G, and
100mg/L gentamicin (all from SigmaChemical Co., St. Louis,
25
27
29
31
33
35
37
39
41
43
45
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
Bo
dy
 w
ei
gh
t (
g)
Control mice
Lk mice
Days of administration of L. kefiri CIDCA 8348
Figure 1: Body weight gain of treated (Lk) and control mice along
21 days of L. kefir CIDCA 8348 administration. No differences were
observed between control mice and Lk mice (𝑃 > 0.05).
MO, USA) for 24 h at 37∘C in a 5% (v/v) CO
2
-95% (v/v)
air atmosphere [37, 38]. Supernatants were collected, cen-
trifuged, and frozen for cytokines (IL-6, IL-17A, TNF-𝛼,
IFN-𝛾, and GM-CSF) measurements (eBioscience Ready Set
Go, France). All assays were performed according to the
manufacturer’s instructions.
3. Results and Discussion
In the present work, six potentially probiotic L. kefiri strains
isolated fromkefirwere studied in order to evaluate both their
safety and antimicrobial properties.
Since hemolysis is a common virulence factor among
pathogens, the first safety parameter evaluated in vitro was
bacterial hemolytic activity. In this study, none of the L. kefiri
strains tested caused 𝛼- or 𝛽-hemolysis (data not shown). In
this genus, hemolytic activity has a very low frequency and
only 𝛼-hemolysis has been reported for lactobacilli isolated
from foods and dairy products [39–41].
Another important feature regarding safety is the sensi-
tivity to antibiotics. The results obtained for L. kefiri strains
are shown in Table 1. All tested bacteria exhibited MIC
values lower than the breakpoints recommended for hetero-
fermentative lactobacilli [20] for tetracycline, clindamycin,
streptomycin, ampicillin, erythromycin, kanamycin, and gen-
tamicin. However, the strains CIDCA 8321 and 8345 were
resistant to chloramphenicol although the amplification of
CAT encoding gene was negative for all the L. kefiri strains
(data not shown). In this regard, Hummel et al. [33] reported
that some lactobacilli strains carrying cat genes were sus-
ceptible to chloramphenicol; meanwhile, in other resistant
strains cat genes could not be amplified. Further research,
such as the study of the distribution of chloramphenicol
MICs, could contribute to determine whether resistance
is acquired (not acceptable strain) or intrinsic (acceptable
strain) according to EFSA [21].
To our knowledge, antibiotic sensitivity of L. kefiri was
evaluated just in two publications. Nawaz et al. [42] studied
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Table 2: Antimicrobial activity of Lactobacillus kefiri strains against pathogens by agar spot test.
Growth inhibition ability
Strain CIDCA 8321 CIDCA 8345 CIDCA 8348 CIDCA 83115 CIDCA 83111 CIDCA 83113
Gram negative bacilli
Pseudomona aeruginosa ++ + ++ + + +
SalmonellaEnteritidis + − + − + +
Shigella flexneri + − + − + −
EHEC − − − − − −
Gram positive bacilli
Listeria monocytogenes + − + − + −
Bacillus cereus ++ + ++ + + ++
Gram positive cocci
Enterococcus faecalis + − + − − −
Staphylococcus aureus ++ + ++ + ++ +
100𝜇m
(a)
100𝜇m
(b)
100𝜇m
(c)
100𝜇m
(d)
Figure 2: Hematoxylin-eosin staining of ileum and colon section. (a) Ileum of control mice; (b) ileum of mice receiving L. kefiri CIDCA
8348 for 21 days; (c) colon of control mice; (d) colon of mice receiving L. kefiri CIDCA 8348 for 21 days. No differences were observed among
groups in any tissue.
one L. kefiri strain isolated from a dairy product, which was
resistant to kanamycin and tetracycline but sensitive to other
antimicrobial agents tested in LSMmedium. Chang et al. [43]
observed that all the L. kefiri strains, among other lactobacilli,
isolated from swine intestines were resistant to tetracycline,
with MIC values higher than 256𝜇gmL−1, and that they
possessed at least one resistance gene. Taking into account
that tetracycline is the most widely used antimicrobial agent
in swine production, its continuous administration might
be selecting tetracycline resistant microorganisms on swine’s
microbiota. This feature and the different origin of our
L. kefiri strains could contribute, at least in part, to the
disagreement between our results and those from other
authors.
The secretion of molecules able to inhibit the growth of
pathogens is a desirable characteristic, among others, for a
potentially probiotic bacteria [44], and it could also be a
technological advantage in the food industry since theymight
be used as functional starter cultures [45, 46]. We evaluated
the pathogen growth inhibition capacity of the six L. kefiri
strains studied. As observed in Table 2, the inhibition profile
was strain dependent, and Gram positive pathogens showed
higher sensibility to L. kefiri strains than Gram negative
bacteria. It is important to notice that the addition of MRS
acidified with HCl or lactic acid to pH 4.3 (final pH reached
by L. kefiri cultures) was not able to produce inhibition
of pathogens in our tests (data not shown). All the strains
inhibited growth of Bacillus cereus and Staphylococcus aureus
but none of them inhibited enterohemorrhagic Escherichia
coli (EHEC). The strains L. kefiri CIDCA 8321, CIDCA 8348,
and CIDCA 83111 were able to inhibit growth of the rest
of the tested pathogens. Many mechanisms associated with
bacterial inhibition have been described for Lactobacillus
species [47]. The production of antimicrobial molecules is
usually strain dependent, which is in accordance with our
results, and the introduction of probiotic bacteria able to
inhibit other microorganisms could have a positive impact in
animal and human health [48, 49].
Up to here, L. kefiri CIDCA 8321, 8348, and 83111
demonstrated to be themost active strains against pathogens;
however, CIDCA8321 showed resistance to chloramphenicol.
In consequence, among the other two strains, we selected
CIDCA 8348 to perform in vivo studies in Swiss mice.
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Figure 3: Secretion of proinflammatory cytokines by intestine and colon explants frommice receiving L. kefiri CIDCA 8348 for 21 days (Lk)
and control mice determined by ELISA. Statistical analysis: one way ANOVA, posttest Bonferroni, 𝛼 = 0.05.
As observed in Figure 1, no differences in body weight
were observed between mice that received 100 𝜇L of a
109 CFUmL−1 suspension of L. kefiriCIDCA8348 (Lk group)
and mice receiving 100 𝜇L of PBS (control group) daily for
21 days. Moreover, there were no differences in food and
water intake between groups (data not shown). In accordance
with these results, Lk group did not show any signs of
pain, lethargy, dehydration, or diarrhea during treatment.
No signs of inflammation or damage were observed in any
organ during necropsy. Length of each mouse’s colon was
measured, since it has been reported that increasing levels
of inflammation result in shortening of the colon [50]. No
significant differences in colon’s length of Lkmice and control
mice were observed (12.4 ± 0.6 versus 12.6 ± 0.8). Moreover,
the histological study of ileum and colon was consistent with
the already described observations; no signs of inflammation,
edema, erosion/ulceration, crypt loss, or infiltration ofmono-
and polymorphonuclear cells [51] were observed in Lk mice’s
tissues (Figure 2), in concordance with previous report by
Bolla et al. [30] who administered this strain as a constituent
of a mixture of five kefir-isolated microorganisms to BALB/c
mice. Additionally, no differences in the secretion levels
for proinflammatory cytokines such as IL-6, IL-17A, IFN-𝛾,
TNF-𝛼, and GM-CSF were observed in the small intestine
and colon explants from Lk and control mice (Figure 3).
On the other hand, no translocation of microorganisms was
observed on blood, spleen, or liver (bacterial counts were
negative), which means that the epithelial barrier was not
disrupted since intestinal permeability was not affected by L.
kefiri CIDCA 8348 administration [52]. Besides, the viable
counts of enterobacteria (3.5±0.8×107 versus 4.8±0.9×107)
and LAB (1.1 ± 0.6 × 107 versus 2.6 ± 0.8 × 107) in the ileum
were comparable between control and treated mice.
4. Conclusion
Taking into account all these findings, we conclude that L.
kefiri CIDCA 8348 isolated from a dairy product present a
great potential as probiotic for human or animal use and can
be used also for producing functional foods.
Conflict of Interests
The authors declare that there is no conflict of interests
regarding the publication of this paper.
6 BioMed Research International
Acknowledgments
This work was supported by Agencia Nacional de Promocio´n
Cient´ıfica y Tecnolo´gica, CONICET, Universidad Nacional
de La Plata (Project 11/X548), and Bordeaux Science Agro,
Ministe`re de l’Agriculture Franc¸ais. P. Carasi is a fellow
of CONICET; M. Dı´az is a fellow of the Comisio´n de
Investigaciones Cient´ıficas de la Provincia de Buenos Aires
(CIC-PBA); G. De Antoni is a researcher of CIC-PBA;
M. Serradell is a member of the Carrera de Investigador
Cient´ıfico y Tecnolo´gico of CONICET. Silvia M. Racedo
and Mar´ıa C. Urdaci are researchers of Bordeaux Science
Agro, Universite´ de Bordeaux. P. Carasi was supported by
Boehringer Ingelheim Fonds (travel grants programme).
References
[1] G. Garrote, A. Abraham, and G. de Antoni, “Microbial inter-
actions in kefir: a natural probiotic drink,” in Biotechnology of
Lactic Acid Bacteria: Novel Applications, F. Mozzi, R. R. Raya,
andG.M.Vignolo, Eds., no. 1980,Wiley-Blackwell, Oxford,UK,
2010.
[2] M. Correa Franco, M. A. Golowczyc, G. L. de Antoni, P. F.
Pe´rez, M. Humen, andM. D. L. A. Serradell, “Administration of
kefir-fermented milk protects mice against Giardia intestinalis
infection,” Journal of Medical Microbiology, vol. 62, part 12, pp.
1815–1822, 2013.
[3] Z. B. Guzel-Seydim, T. Kok-Tas, A. K.Greene, andA.C. Seydim,
“Review: functional properties of kefir,”Critical Reviews in Food
Science and Nutrition, vol. 51, no. 3, pp. 261–268, 2011.
[4] E. J. Kakisu, A. G. Abraham, P. F. Pe´rez, and G. L. de Antoni,
“Inhibition of Bacillus cereus in milk fermented with kefir
grains,” Journal of Food Protection, vol. 70, no. 11, pp. 2613–2616,
2007.
[5] C. G. Vinderola, J. Duarte, D. Thangavel, G. Perdigo´n, E.
Farnworth, and C. Matar, “Immunomodulating capacity of
kefir,” Journal of Dairy Research, vol. 72, no. 2, pp. 195–202, 2005.
[6] FAO/WHO, Health and Nutritional Properties of Probiotics in
Food Including PowderMilk with Live Lactic Acid Bacteria, 2001,
http://www.who.int/foodsafety/publications/fs management/
en/probiotics.pdf.
[7] M. Bernardeau, J. P. Vernoux, S. Henri-Dubernet, and M.
Gue´guen, “Safety assessment of dairy microorganisms: the
Lactobacillus genus,” International Journal of FoodMicrobiology,
vol. 126, no. 3, pp. 278–285, 2008.
[8] M. Dusˇkova´, O. Sˇedo, K. Ksˇicova´, Z. Zdra´hal, and R.
Karpı´sˇkova´, “Identification of lactobacilli isolated from food
by genotypic methods and MALDI-TOF MS,” International
Journal of Food Microbiology, vol. 159, no. 2, pp. 107–114, 2012.
[9] B. Corthe´sy, H. R. Gaskins, and A. Mercenier, “Cross-talk
between probiotic bacteria and the host immune system,”
Journal of Nutrition, vol. 137, no. 3, pp. 781–790, 2007.
[10] J. M. Wells, “Immunomodulatory mechanisms of lactobacilli,”
Microbial Cell Factories, vol. 10, supplement 1, p. S17, 2011.
[11] A. A. Hugo, E. Kakisu, G. L. de Antoni, and P. F. Pe´rez, “Lac-
tobacilli antagonize biological effects of enterohaemorrhagic
Escherichia coli in vitro,” Letters in AppliedMicrobiology, vol. 46,
no. 6, pp. 613–619, 2008.
[12] M. A. Humen, G. L. de Antoni, J. Benyacoub et al., “Lacto-
bacillus johnsonii La1 antagonizes Giardia intestinalis in vivo,”
Infection and Immunity, vol. 73, no. 2, pp. 1265–1269, 2005.
[13] A. L. Servin, “Antagonistic activities of lactobacilli and bifi-
dobacteria against microbial pathogens,” FEMS Microbiology
Reviews, vol. 28, no. 4, pp. 405–440, 2004.
[14] EFSA Panel on Biological Hazards (BIOHAZ), “Scientific opin-
ion on the maintenance of the list of QPS biological agents
intentionally added to food and feed (2012 update),” EFSA
Journal, vol. 10, no. 12, p. 3020, 2012.
[15] P. A. Fradiani, A. Petrucca, F. Ascenzioni et al., “Endocardi-
tis caused by Lactobacillus jensenii in an immunocompetent
patient,” Journal of Medical Microbiology, vol. 59, no. 5, pp. 607–
609, 2010.
[16] F. Gouriet, M. Million, M. Henri, P.-E. Fournier, and D. Raoult,
“Lactobacillus rhamnosus bacteremia: an emerging clinical
entity,” European Journal of Clinical Microbiology and Infectious
Diseases, vol. 31, no. 9, pp. 2469–2480, 2012.
[17] M. H. Land, K. Rouster-Stevens, C. R. Woods, M. L. Cannon,
J. Cnota, and A. K. Shetty, “Lactobacillus sepsis associated with
probiotic therapy,” Pediatrics, vol. 115, no. 1, pp. 178–181, 2005.
[18] I. Sua´rez-Garc´ıa, A. Sa´nchez-Garc´ıa, L. Soler, E. Malmierca,
and J. Go´mez-Cerezo, “Lactobacillus jensenii bacteremia and
endocarditis after dilatation and curettage: case report and
literature review,” Infection, vol. 40, no. 2, pp. 219–222, 2012.
[19] S. Mayrhofer, K. J. Domig, C. Mair, U. Zitz, G. Huys, and
W. Kneifel, “Comparison of broth microdilution, Etest, and
agar disk diffusion methods for antimicrobial susceptibility
testing of Lactobacillus acidophilus group members,” Applied
and Environmental Microbiology, vol. 74, no. 12, pp. 3745–3748,
2008.
[20] EFSA Panel on Additives and Products or Substances used in
Animal Feed (FEEDAP), “Guidance on the assessment of bac-
terial susceptibility to antimicrobials of human and veterinary
importance,” EFSA Journal, vol. 10, no. 6, pp. 1–10, 2012.
[21] EFSA Panel on Additives and Products or Substances used
in Animal Feed (FEEDAP), “Technical guidance—update of
the criteria used in the assessment of bacterial resistance to
antibiotics of human or veterinary importance,” EFSA Journal,
vol. 732, pp. 1–15, 2008.
[22] A. Bosch, M. A. Golowczyc, A. G. Abraham, G. L. Garrote,
G. L. de Antoni, and O. Yantorno, “Rapid discrimination of
lactobacilli isolated from kefir grains by FT-IR spectroscopy,”
International Journal of Food Microbiology, vol. 111, no. 3, pp.
280–287, 2006.
[23] G. L. Garrote, A. G. Abraham, and G. L. de Antoni, “Chemical
and microbiological characterisation of kefir grains,” Journal of
Dairy Research, vol. 68, no. 4, pp. 639–652, 2001.
[24] M. F. Hamet, A. Londero, M. Medrano et al., “Application
of culture-dependent and culture-independent methods for
the identification of Lactobacillus kefiranofaciens in microbial
consortia present in kefir grains,” FoodMicrobiology, vol. 36, no.
2, pp. 327–334, 2013.
[25] G. L. Garrote, M. A. Serradell, A. G. Abraham, M. C. An˜on,
C. A. Fossati, and G. L. de Antoni, “Development of an
immunochemical method to detect Lactobacillus kefir,” Food
and Agricultural Immunology, vol. 16, no. 3, pp. 221–233, 2005.
[26] M. A. Golowczyc, P. Mobili, G. L. Garrote, A. G. Abraham,
and G. L. de Antoni, “Protective action of Lactobacillus kefir
carrying S-layer protein against Salmonella enterica serovar
Enteritidis,” International Journal of Food Microbiology, vol. 118,
no. 3, pp. 264–273, 2007.
[27] P. Carasi, F.M. Trejo, P. F. Pe´rez, G. L. de Antoni, andM.D. L. A.
Serradell, “Surface proteins from Lactobacillus kefir antagonize
BioMed Research International 7
in vitro cytotoxic effect ofClostridium difficile toxins,”Anaerobe,
vol. 18, no. 1, pp. 135–142, 2012.
[28] M. A. Golowczyc, J. Silva, P. Teixeira, G. L. de Antoni, and A.
G. Abraham, “Cellular injuries of spray-dried Lactobacillus spp.
isolated from kefir and their impact on probiotic properties,”
International Journal of Food Microbiology, vol. 144, no. 3, pp.
556–560, 2011.
[29] M. A. Golowczyc, J. Silva, A. G. Abraham, G. L. de Antoni, and
P. Teixeira, “Preservation of probiotic strains isolated from kefir
by spray drying,” Letters in Applied Microbiology, vol. 50, no. 1,
pp. 7–12, 2010.
[30] P. A. Bolla, M. D. L. A. Serradell, P. J. de Urraza, and G. L.
de Antoni, “Effect of freeze-drying on viability and in vitro
probiotic properties of a mixture of lactic acid bacteria and
yeasts isolated from kefir,” Journal of Dairy Research, vol. 78, no.
1, pp. 15–22, 2011.
[31] P. Carasi, N. M. Ambrosis, G. L. de Antoni, P. Bressollier, M.
C. Urdaci, and M. D. L. A. Serradell, “Adhesion properties
of potentially probiotic Lactobacillus kefiri to gastrointestinal
mucus,” Journal of Dairy Research, vol. 81, no. 1, pp. 16–23, 2014.
[32] ISO (International Organization for Standardization), “Milk
and milk products—determination of the minimal inhibitory
concentration (MIC) of antibiotics applicable to bifidobac-
teria and non-enterococcal lactic acid bacteria (LAB),” ISO
10932:2010 (IDF 223:2010), 2010.
[33] A. S. Hummel, C. Hertel,W.H.Holzapfel, and C.M. A. P. Franz,
“Antibiotic resistances of starter and probiotic strains of lactic
acid bacteria,” Applied and Environmental Microbiology, vol. 73,
no. 3, pp. 730–739, 2007.
[34] U. Schillinger and F. K. Lu¨cke, “Antibacterial activity of Lac-
tobacillus sake isolated from meat,” Applied and Environmental
Microbiology, vol. 55, no. 8, pp. 1901–1906, 1989.
[35] D. J. Langford, A. L. Bailey,M. L. Chanda et al., “Coding of facial
expressions of pain in the laboratory mouse,” Nature Methods,
vol. 7, no. 6, pp. 447–449, 2010.
[36] P. A. Bolla, P. Carasi, M. D. L. A. Bolla, G. L. de Antoni, and
M. Serradell, “Protective effect of a mixture of kefir-isolated
lactic acid bacteria and yeasts in a hamstermodel ofClostridium
difficile infection,” Anaerobe, vol. 21, pp. 28–33, 2013.
[37] L. Chatelais, A. Jamin, C. G. Guen, J. Lalle`s, I. le Hue¨rou-Luron,
and G. Boudry, “The level of protein in milk formula modifies
ileal sensitivity to LPS later in life in a piglet model,” PLoS ONE,
vol. 6, no. 5, Article ID e19594, 2011.
[38] S. Dionne, S. Laberge, C. Deslandres, and E. G. Seidman,
“Modulation of cytokine release from colonic explants by
bacterial antigens in inflammatory bowel disease,” Clinical and
Experimental Immunology, vol. 133, no. 1, pp. 108–114, 2003.
[39] D. B. Adimpong, D. S. Nielsen, K. I. Sørensen, P. M. F.
Derkx, and L. Jespersen, “Genotypic characterization and safety
assessment of lactic acid bacteria from indigenous African
fermented food products,” BMCMicrobiology, vol. 12, no. 1, pp.
75–86, 2012.
[40] P. M. Kaktcham, N. F. Zambou, F. M. Tchouanguep, M. El-
Soda, and M. I. Choudhary, “Antimicrobial and safety proper-
ties of lactobacilli isolated from two Cameroonian traditional
fermented foods,” Scientia Pharmaceutica, vol. 80, no. 1, pp. 189–
203, 2012.
[41] P. A. Maragkoudakis, G. Zoumpopoulou, C. Miaris, G. Kalant-
zopoulos, B. Pot, and E. Tsakalidou, “Probiotic potential of Lac-
tobacillus strains isolated from dairy products,” International
Dairy Journal, vol. 16, no. 3, pp. 189–199, 2006.
[42] M. Nawaz, J. Wang, A. Zhou et al., “Characterization and
transfer of antibiotic resistance in lactic acid bacteria from
fermented food products,” Current Microbiology, vol. 62, no. 3,
pp. 1081–1089, 2011.
[43] Y.-C. Chang, C.-Y. Tsai, C.-F. Lin, Y.-C. Wang, I.-K. Wang,
and T.-C. Chung, “Characterization of tetracycline resistance
lactobacilli isolated from swine intestines at western area of
Taiwan,” Anaerobe, vol. 17, no. 5, pp. 239–245, 2011.
[44] C. Dunne, L. O’Mahony, L. Murphy et al., “In vitro selection
criteria for probiotic bacteria of human origin: correlation with
in vivo findings,”TheAmerican Journal of Clinical Nutrition, vol.
73, no. 2, supplement, pp. 386S–392S, 2001.
[45] R. Rubio, A. Jofre´, B. Mart´ın, T. Aymerich, and M. Garriga,
“Characterization of lactic acid bacteria isolated from infant
faeces as potential probiotic starter cultures for fermented
sausages,” Food Microbiology, vol. 38, pp. 303–311, 2014.
[46] A. A. Argyri, G. Zoumpopoulou, K.-A. G. Karatzas et al., “Selec-
tion of potential probiotic lactic acid bacteria from fermented
olives by in vitro tests,” FoodMicrobiology, vol. 33, no. 2, pp. 282–
291, 2013.
[47] S. Lebeer, J. Vanderleyden, and S. C. J. de Keersmaecker, “Genes
and molecules of lactobacilli supporting probiotic action,”
Microbiology and Molecular Biology Reviews, vol. 72, no. 4, pp.
728–764, 2008.
[48] L. de Vuyst and F. Leroy, “Bacteriocins from lactic acid bacteria:
production, purification, and food applications,” Journal of
Molecular Microbiology and Biotechnology, vol. 13, no. 4, pp.
194–199, 2007.
[49] M. P. Zacharof and R. W. Lovitt, “Bacteriocins produced by
lactic acid bacteria: a review article,” APCBEE Procedia, vol. 2,
pp. 50–56, 2012.
[50] C. A. Jacobi, S. Grundler, C. J. Hsieh et al., “Quorum sensing in
the probiotic bacteriumEscherichia coliNissle 1917 (Mutaflor)—
evidence that furanosyl borate diester (AI-2) is influencing
the cytokine expression in the DSS colitis mouse model,” Gut
Pathogens, vol. 4, no. 1, article 8, 2012.
[51] T. T. Hove, B. van den Blink, I. Pronk, P. Drillenburg, M. P.
Peppelenbosch, and S. J. H. van Deventer, “Dichotomal role
of inhibition of p38 MAPK with SB 203580 in experimental
colitis,” Gut, vol. 50, no. 4, pp. 507–512, 2002.
[52] L. C.-H. Yu, J.-T. Wang, S.-C. Wei, and Y. H. Ni, “Host-
microbial interactions and regulation of intestinal epithelial
barrier function: from physiology to pathology,”World Journal
of Gastroenterology, vol. 3, no. 1, pp. 27–43, 2012.
Submit your manuscripts at
http://www.hindawi.com
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Anatomy 
Research International
Peptides
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation 
http://www.hindawi.com
 International Journal of
Volume 2014
Zoology
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Molecular Biology 
International 
Genomics
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Bioinformatics
Advances in
Marine Biology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Signal Transduction
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Evolutionary Biology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Biochemistry 
Research International
Archaea
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Genetics 
Research International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Advances in
Virolog y
Hindawi Publishing Corporation
http://www.hindawi.com
Nucleic Acids
Journal of
Volume 2014
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Enzyme 
Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
International Journal of
Microbiology
